Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results